Matthew Caufield Analyst Performance

Matthew Caufield is a Vice President of Equity Research at H.C. Wainwright, having joined the firm in 2018. Mr. Caufield’s research focuses on small and mid-cap biotechnology companies including innovations in the ophthalmology and gastrointestinal industries. Prior to joining H.C. Wainwright, Mr. Caufield was an Equity Research Associate at Piper Sandler & Co. assisting in the coverage of small and mid-cap biotechnology companies. Mr. Caufield previously worked as a Senior Wealth Strategy Associate in Private Wealth Management at UBS, and as an Investment Service Associate at JPMorgan Chase & Co. Mr. Caufield is a published scientist, and his educational background includes an MBA from the S.C. Johnson Graduate School of Management at Cornell University, a M.S. in Neurobiology from Northwestern University, and a B.S. in Neuroscience from Colgate University.